ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0399

Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease
Abstract Number: 1783

National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017
Abstract Number: 0352

Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
Abstract Number: 0566

Natural Language Processing of Electronic Health Record Notes Captures Forced Vital Capacity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 0328

Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Abstract Number: 1894

Natural Language Processing Tool for Extraction of Patient-Reported Outcomes from a National Multi-Electronic Health Records Registry
Abstract Number: PP03

Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Abstract Number: 1171

Needs Assessment of a Rheumatology Curriculum for Internal Medicine Residents
Abstract Number: 0421

Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Abstract Number: L12

Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Abstract Number: 1002

Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis
Abstract Number: 1883

Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Abstract Number: 0417

Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Abstract Number: 1868

Neutrophil Extracellular Trap Formation in Patients with Vasculitis
Abstract Number: 1531

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].